ImmunityBio (NASDAQ: IBRX) announced it secured $100 million in financing through two transactions, according to a company press release.

The immunotherapy company received $75 million in non-dilutive funding under its existing Revenue Interest Purchase Agreement with Oberland Capital, bringing total committed capital under the agreement to $375 million. The amended agreement maintains existing terms with a modest increase in the royalty payback rate while maintaining the royalty cap.

Simultaneously, Nant Capital, an entity affiliated with Executive Chairman Patrick Soon-Shiong, converted $25 million of an outstanding promissory note into 4.6 million shares of common stock. This conversion reduces debt under a $505 million promissory note from December 2024.

"This additional non-dilutive financing gives us the capacity to continue scaling our commercial efforts and expanding globally following recent ANKTIVA approvals," said Richard Adcock, President and CEO of ImmunityBio.

The company's drug ANKTIVA, in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer, has received approval or authorization across five regulatory jurisdictions representing approximately 34 countries. These include the United States (April 2024), United Kingdom (July 2025), Saudi Arabia (January 2026), European Union (February 2026), and Macau (March 2026).

Saudi Arabia became the first jurisdiction to authorize ANKTIVA for metastatic non-small cell lung cancer in combination with checkpoint inhibitors, also in January 2026.

ImmunityBio is a commercial-stage immunotherapy company focused on developing treatments designed to activate patients' immune systems against cancer and infectious diseases.